IRX Therapeutics

Business Services · Massachusetts, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

1035 Cambridge St Ste 18A, Cambridge, Ma...

Phone Number

(212) 582-1199

Revenue

$5 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1

About IRX Therapeutics

Ernexa Therapeutics Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that develops innovative cell therapies for the treatment of advanced cancer and autoimmune disease. The company utilizes a proprietary platform to engineer induced pluripotent stem cells (iPSCs) and differentiate them into synthetic induced mesenchymal stem cells (iMSCs). These allogeneic, off-the-shelf therapies are designed to home to sites of tumor or inflammation to deliver therapeutic cytokines. Its pipeline includes ERNA-101, targeting platinum-resistant ovarian cancer by delivering IL-7 and IL-15, and ERNA-201, designed to treat rheumatoid arthritis by delivering IL-10 to sites of inflammation.Explore more
IRX Therapeutics's Social MediaPopular SearchesIrx Therapeutics IncSIC Code 87,873NAICS Code 54,541Show more

Is IRX Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to IRX Therapeutics

Compare insights from companies similar to IRX Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

IRX Therapeutics

$5M
11-50
Private
-
1994
N/A
$6.3M
1-10
Private
$6M
2019
$5.4M
1-10
Private
$16.4M
2013
John Didsbury, Founder & Chief Executive Officer at T3D Therapeutics
John DidsburyFounder & CEO
<$5M
1-10
Private
<$5M
2004
<$5M
11-50
Private
-
2006
N/A
<$5M
1-10
Private
$10.7M
2014
Robert Alonso, Founder & Chief Executive Officer at Mitochon Pharmaceuticals
Robert AlonsoFounder & CEO
Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

IRX Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

IRX Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about IRX Therapeutics.

IRX Therapeutics Tech Stack

A closer look at the technologies used by IRX Therapeutics

Top Business Services Companies

Frequently Asked Questions Regarding IRX Therapeutics

What is IRX Therapeutics's official website?
IRX Therapeutics's official website is www.irxtherapeutics.com
What is IRX Therapeutics's Revenue?
IRX Therapeutics's revenue is $5 Million
What is IRX Therapeutics's SIC code?
IRX Therapeutics's SIC: 87,873
What is IRX Therapeutics's NAICS code?
IRX Therapeutics's NAICS: 54,541
How many employees does IRX Therapeutics have?
IRX Therapeutics has 11-50 employees
What industry does IRX Therapeutics belong to?
IRX Therapeutics is in the industry of: Business Services, Research & Development
What is IRX Therapeutics competition?
IRX Therapeutics top competitors include: KeifeRx, Btdd, Mitochon Pharmaceuticals, Neuronascent
What technology does IRX Therapeutics use?
Some of the popular technologies that IRX Therapeutics uses are: prismic, Microsoft 365, GoDaddy DNS, ASP.NET
How do I contact IRX Therapeutics?
IRX Therapeutics contact info: Phone number: (212) 582-1199 Website: www.irxtherapeutics.com
What does IRX Therapeutics do?

Ernexa Therapeutics Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that develops innovative cell therapies for the treatment of advanced cancer and autoimmune disease. The company utilizes a proprietary platform to engineer induced pluripotent stem cells (iPSCs) and differentiate them into synthetic induced mesenchymal s... tem cells (iMSCs). These allogeneic, off-the-shelf therapies are designed to home to sites of tumor or inflammation to deliver therapeutic cytokines. Its pipeline includes ERNA-101, targeting platinum-resistant ovarian cancer by delivering IL-7 and IL-15, and ERNA-201, designed to treat rheumatoid arthritis by delivering IL-10 to sites of inflammation.Read More

What are IRX Therapeutics social media links?
IRX Therapeutics Linkedin page
Is IRX Therapeutics a public company?
IRX Therapeutics is private company therefore does not currently have an official ticker symbol
See more information about IRX Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.